EGFR and non-small cell lung carcinoma: Of these, tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR) mutated or anaplastic lymphoma kinase (ALK) translocated NSCLC were already successfully implemented into the clinical setting.